Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA SANDI HOLDINGS LIMITED
中國三迪控股有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 910)

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors ("**Directors**") of China Sandi Holdings Limited (the "**Company**") is pleased to announce that with effect from 15 July 2026, Dr. Poon Wai Kong ("**Dr. Poon**") has been appointed as an executive Director.

The biographical details of Dr. Poon are set out below:

Dr. Poon, aged 54, has over 20 years of experience in financial management, corporate governance, company secretarial practice and corporate finance, where Dr. Poon served as non-executive director and independent non-executive director for several Hong Kong listed companies of various industries and worked as financial controller and held various accounting related roles at different companies over the years. Dr. Poon has been acting as the company secretary of the Company since 11 March 2026.

Dr. Poon holds a Doctor of Business Administration from City University of Hong Kong, a Master of Professional Accounting and Corporate Governance and a Master of Business Administration from City University of Hong Kong, a Master of Practising Accounting from Monash University, Australia, and a B.Sc. (Economics) & Diploma in Economics from the University of London, the United Kingdom. He is currently a fellow member of the Hong Kong Institute of Certified Public Accountants, a fellow member of Certified Practising Accountants Australia, and a qualified member of The Chartered Governance Institute in the United Kingdom and Ireland.

Dr. Poon has entered into a service contract with the Company for a period of 3 years commencing from 15 July 2026, which may be terminated by either party giving three-month's prior written notice. His appointment is subject to retirement by rotation and re-election at the next following annual general meeting of the Company under the bye-laws of the Company. Dr. Poon is entitled to a director's fee of HK$20,000 per month, which is determined by the remuneration committee of the Board and the Board on the basis of his experience, knowledge, qualifications, duties and responsibilities and the prevailing market conditions.

As at the date of this announcement, Dr. Poon (a) does not have any interests in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (b) does not have any relationship with any Directors or senior management or substantial shareholders (as defined in the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**")) or controlling shareholders (as defined in the Listing Rules) of the Company; (c) does not have any other major appointments and professional qualifications; and (d) did not hold any directorship in other publicly listed companies within the last three years. As at the date of this announcement, save as disclosed above, Dr. Poon does not hold any other position in the Company or other members of the Company and its subsidiaries.

Save as disclosed in this announcement, there is no other matter in relation to the appointment of Dr. Poon that needs to be brought to the attention of the shareholders of the Company, and there is no other information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to extend its welcome to Dr. Poon for joining the Board.

CONTINUED SUSPENSION IN TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 1 April 2025 and will remain suspended until further notice.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.

By order of the Board
China Sandi Holdings Limited
Guo Jiadi
Chairman

Hong Kong, 15 July 2026

As at the date of this announcement, the Board comprises Mr. Guo Jiadi, Mr. Wang Chao and Dr. Poon Wai Kong, being the executive Directors; Ms. Amika Lan E Guo, being the non-executive Director; Mr. Liao Yiyi, Ms. Yu Huaxiu and Ms. Zhang Jianchan, being the independent non-executive Directors.